Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
前日終値
$26.36
−$0.81 · -2.98%
日中の時刻はETです。市場データは遅延する場合があります。
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
日中レンジ
現在 $26.36
52週レンジ
現在 $26.36
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
79
割安
センチメント
55
まちまち
リスク
43
やや高いリスク
モメンタム
59
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
日中レンジ
現在 $26.36
52週レンジ
現在 $26.36
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 3.76億 USD | 1.97億 USD | 5960.6万 USD | 368.6万 USD | — |
| 売上原価 | 3669.5万 USD | 1912.8万 USD | 498.7万 USD | 75.4万 USD | 76.3万 USD |
| 粗利益 | 3.39億 USD | 1.77億 USD | 5461.9万 USD | 293.2万 USD | −76.3万 USD |
| 研究開発 | 7705.1万 USD | 7642万 USD | 1.11億 USD | 1.82億 USD | 1.46億 USD |
| 販売・一般管理 | 2.75億 USD | 2.29億 USD | 1.85億 USD | 1.22億 USD | 6097.1万 USD |
| 営業費用 | 3.52億 USD | 3.06億 USD | 2.96億 USD | 3.05億 USD | 2.06億 USD |
| 受取利息 | — | — | — | — | 17.3万 USD |
| 支払利息 | 1208.3万 USD | 2716.8万 USD | 2971.2万 USD | 1565.2万 USD | — |
| 減価償却費と償却費 | 466.7万 USD | 259.9万 USD | 75万 USD | 93.4万 USD | 45.4万 USD |
| 営業利益 | −1222.7万 USD | −1.28億 USD | −2.41億 USD | −3.02億 USD | −2.07億 USD |
| 純利益 | −1614.1万 USD | −1.4億 USD | −2.62億 USD | −3.11億 USD | −2.06億 USD |
会社概要が更新されました 2026年11月22日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$41.80
上昇余地(58.57%)この株式へのエクスポージャーを報告している上場投資信託です。
iShares Core S&P Small-Cap ETFIJR1.82億0.18%987億 USD0.06%$131.25-2.53%
Vanguard Morningstar Total Stock Market ETFVTI9179.97万0.01%6893億 USD0.03%$340.02-3.52%
State Street SPDR S&P Biotech ETFXBI8411.11万0.87%96.36億 USD0.35%$140.18-2.73%
iShares Russell 2000 ETFIWM8096.49万0.11%715.37億 USD0.19%$256.61-2.88%
Vanguard Extended Market ETFVXF4161.41万0.04%302億 USD0.05%$211.44-3.21%
iShares Russell 2000 Growth ETFIWO2936.17万0.22%127.32億 USD0.24%$320.43-3.57%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM2831.29万0.19%152.94億 USD0.03%$50.99-2.58%
Simplify Health Care ETFPINK2750.25万8.89%3.09億 USD0.51%$37.00-1.44%
iShares Core S&P Small-Cap ETFIJR
Vanguard Morningstar Total Stock Market ETFVTI
State Street SPDR S&P Biotech ETFXBI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Simplify Health Care ETFPINKAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。